Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients

The introduction of immunotherapy using an anti-GD2 antibody (dinutuximab, ch14.18) has significantly improved survival rates for high-risk neuroblastoma patients. However, this improvement in survival is accompanied by a substantial immunotherapy-related toxicity burden. The primary objective of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Blom, Thomas, Lurvink, Roosmarijn, Aleven, Leonie, Mensink, Maarten, Wolfs, Tom, Dierselhuis, Miranda, van Eijkelenburg, Natasha, Kraal, Kathelijne, van Noesel, Max, van Grotel, Martine, Tytgat, Godelieve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925836/
https://www.ncbi.nlm.nih.gov/pubmed/33680926
http://dx.doi.org/10.3389/fonc.2020.601076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925836/
https://www.ncbi.nlm.nih.gov/pubmed/33680926
http://dx.doi.org/10.3389/fonc.2020.601076

Ejemplares similares